Definitive Healthcare (DH) has wrapped up FY 2025 with Q4 revenue of US$61.5 million and a basic EPS loss of US$0.09, alongside a trailing twelve month loss of US$1.30 per share on US$241.5 million of revenue. Over recent periods, the company has reported quarterly revenue between US$59.2 million and US$62.7 million, while basic EPS has ranged from a loss of US$0.07 to a loss of US$1.12. For investors, the latest results keep attention on when margins might begin to close the gap between a relatively stable top line and ongoing losses.

See our full analysis for Definitive Healthcare.

With the headline numbers on the table, the next step is to see how this earnings profile compares with the most common narratives around Definitive Healthcare and where those stories might need an update.

Losses Still Heavy At US$138.9 Million Over The Year

• On a trailing twelve month basis, Definitive Healthcare booked a net loss of US$138.9 million on US$241.5 million of revenue, which works out to a sizeable loss relative to the business it is bringing in.
• Consensus narrative talks about earnings eventually turning positive, but the recent loss profile, including quarterly net losses between US$7.6 million and US$107.2 million in FY 2025, shows the company is still some distance from the profit margins implied in those long term models.
  • Analysts discuss profit margins converging on an 8.8% industry level over time, yet the latest four quarters together added up to a loss of US$138.9 million, which pulls in the opposite direction.
  • For you as a shareholder or potential shareholder, that means any optimistic view on future profitability has to be weighed against the depth of these recent losses and the fact that the business is still firmly in loss making territory today.

Revenue Treads Water While Forecasts Call For Pressure

• Quarterly revenue in FY 2025 sat in a tight band between US$59.2 million and US$61.5 million, and the trailing twelve month revenue figure of US$241.5 million is close to the US$247.9 million reported one year earlier, lining up with analyst expectations for revenue decline of about 2.5% per year ahead.
• Bears argue that shrinking or flat revenue combined with competitive and regulatory headwinds will keep a lid on the top line, and the recent data aligns with that concern rather than challenging it.
  • Revenue guidance and commentary referenced in the consensus narrative include a 5% year over year decline for Q2 2025 and full year guidance for a 5% to 6% decline, which fits the bearish view that growth in the core subscription base is under strain.
  • At the same time, the company’s reliance on a multi year data partnership that contributes only a few percentage points of quarterly growth suggests that without such deals, organic revenue would be under even more pressure, which is exactly what cautious investors are focused on.

Bears point to these revenue trends as a warning sign that growth could stay constrained even if costs improve, and that is the core of the more cautious story around DH right now. 🐻 Definitive Healthcare Bear Case

Share Price At US$1.28 Versus Low P/S And DCF Fair Value

• With the share price at US$1.28 and the company trading on a P/S of 0.5x compared with 2.2x for the US Healthcare Services industry and 2.1x for peers, DH also sits below a DCF fair value of about US$3.39 and the allowed analyst price target reference of US$3.03.
• Bullish investors frame this valuation gap as a potential opportunity if the business can move closer to the earnings levels discussed in long term scenarios, but the current loss making profile means that view leans heavily on future execution.
  • The valuation data points to the shares sitting roughly 62.3% below the DCF fair value estimate, which is the kind of discount bulls highlight when they argue the market is overly focused on current losses.
  • On the other hand, the same dataset shows losses growing at about 56.4% per year over the past five years, so anyone leaning into the bullish case needs to be comfortable with the idea that the market may be pricing in the risk that this negative trend persists longer than analysts expect.

Supporters of the bullish view see the low P/S and gap to DCF fair value as a setup where improved execution could matter a lot more than modest revenue shifts. 🐂 Definitive Healthcare Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Definitive Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of caution and optimism here feels familiar, this is the moment to look at the numbers yourself and move quickly to shape your own view. You can start by weighing the positives investors are already watching closely through our breakdown of 4 key rewards.

See What Else Is Out There

Definitive Healthcare is still posting sizeable losses on relatively flat revenue and sits well below earnings levels often discussed in more optimistic scenarios.

If you are uneasy about that mix of ongoing losses and pressured growth, take a few minutes now to look through our 78 resilient stocks with low risk scores that focus on steadier fundamentals and potentially lower risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.